Neuralstem Cultura de la Empresa

Dr. Thomas G. Hazel, Tom, Ph.D. has been Senior Vice President of Research at Neuralstem, Inc since 2008. Dr. Hazel served as an Executive Vice President of Research of Neuralstem, Inc. since July 2008. Dr. Hazel manages Neuralstem's upcoming clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease), and complete development of Neuralstem's small molecule neurogenesis compound targeted to treat depression. Before Neuralstem in 1998, Dr. Hazel was a Senior Staff Scientist at the National Institute of Health. He came to Neuralstem after a four year stint as Chief Science Officer at Innovative Biosensors, Inc., in Maryland. He also served as Senior Director for Research and Development of Innovative Biosensors Inc. Dr. Hazel has over 12 years of laboratory research and management experience. He has held senior level research positions in a wide range of fields, including molecular genetics and cell culture. Dr. Hazel's area of expertise includes engineering of human cell lines and the manufacturing and storage of cell culture based reagents. He is named on several pending patents and has over 10 scientific publications. Dr. Hazel received a Ph.D. in Genetics from The University of Illinois College of Medicine and completed his postdoctoral work at the NIH.

Dr. Karl Y. Johe, Ph.D. Co-founded Neuralstem, Inc. in 1996 and has been its Chief Scientific Officer since 1996. Dr. Johe has over 15 years of research and laboratory experience. As a recognized expert in neural stem cell technology, he is the sole inventor of Neuralstem's granted stem cell patents and is responsible for strategic planning and development of its therapeutic products. From 1993 to January 1997, he served as a Staff Scientist at the Laboratory of Molecular Biology of the National Institute of Neurological Disease and Stroke in Bethesda, Maryland. While holding this position, he conducted research on the isolation of neural stem cells, the elucidation of mechanisms directing cell type specification of CNS stem cells and the establishment of an in vitro model of mammalian neurogenesis. He served as the Chairman of Neuralstem, Inc. from 1996 to June 13, 2016 and served as its Director from 1996 to August 31, 2016. Dr. Johe holds a Bachelor of Arts Degree in Chemistry from the University of Kansas, a Master's Degree from the University of Kansas and a Doctorate was received from the Albert Einstein College of Medicine.

Jonathan Jones serves as the CFO of Neuralstem, Inc.. Jonathan started at Neuralstem, Inc. in May of 2015. Jonathan currently resides in the Washington D.C. Metro Area.